PSP Research
PSP Research reported 44 stocks worth $146M in its 13F filing for Q3 2026, filed Oct 21, 2026. Its largest holdings are SGOV (48.3%), XBI (41.8%) and SERA (3.4%). Compared with Q2 2026, the fund opened new positions in SERA, trimmed XBI, HALO and EXEL and sold out of IRON, RAPP and RARE.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 4 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  SGOV Ishares TR | $70.5M | 48.3% | 700K | No change | 4 of 4 | |
| 2 |  XBI Spdr Series Trust | $60.9M | 41.8% | 387K | −184K (−32%) | 3 of 4 | |
| 3 |  SERA Sera Prognostics Inc | $5M | 3.4% | 2.4M | New position | 2 of 4 | |
| 4 |  HALO Halozyme Therapeutics Inc | $331K | 0.2% | 3,000 | −4,000 (−57%) | 4 of 4 | |
| 5 |  MDGL Madrigal Pharmaceuticals Inc | $302K | 0.2% | 600 | No change | 4 of 4 | |
| 6 |  EXEL Exelixis Inc | $292K | 0.2% | 5,000 | −3,000 (−38%) | 4 of 4 | |
| 7 |  RPRX Royalty Pharma PLC | $292K | 0.2% | 5,000 | −6,000 (−55%) | 4 of 4 | |
| 8 |  ARGX Argenx SE | $288K | 0.2% | 300 | −341 (−53%) | 4 of 4 | |
| 9 |  NRIX Nurix Therapeutics Inc | $285K | 0.2% | 12K | −13K (−52%) | 4 of 4 | |
| 10 |  TGTX TG Therapeutics Inc | $279K | 0.2% | 5,000 | −5,000 (−50%) | 4 of 4 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
 IRON Disc Medicine Inc | $585K | 8,000 |
 RAPP Rapport Therapeutics Inc | $583K | 14K |
 RARE Ultragenyx Pharmaceutical in | $568K | 17K |
 GLUE Monte Rosa Therapeutics Inc | $557K | 23K |
 IONS Ionis Pharmaceuticals Inc | $539K | 6,800 |
🔒 Free account: see all 30.
Reported value
last 4 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Oct 21, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →PSP Research 13F FAQ
What does PSP Research own?
PSP Research reported 44 stocks worth $146M in its 13F filing for Q3 2026, filed Oct 21, 2026. Its largest holdings are SGOV (48.3%), XBI (41.8%) and SERA (3.4%). The table above lists every position in the filing (the top 10 without an account).
What did PSP Research buy and sell in Q3 2026?
Compared with Q2 2026: 1 new positions, 0 added to, 27 trimmed and 32 sold out. New positions include SERA. It sold all of IRON, RAPP and RARE.
When will PSP Research file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is PSP Research's portfolio worth?
The Q3 2026 filing reports $146M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.